Announcements Trials
Browse Landscape

Phase

Phase 3 4Phase NA 1Phase 2/3 1Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1

Interventions

Cytarabine 25Cyclophosphamide 23venetoclax 16Methotrexate 15Daunorubicin 14Dexamethasone 13Vincristine 11Etoposide 11Azacitidine 10Idarubicin 9Decitabine 9Busulfan 9fludarabine 8Radiotherapy 8Prednisone 8Stem Cell Transplantation 7Mercaptopurine 7Doxorubicin 7Asparaginase 7pegaspargase 6fludarabine phosphate 6blinatumomab 6Granulocyte Colony-Stimulating Factor 6Gemtuzumab 6Filgrastim 6Thiotepa 5Methylprednisolone 5Dasatinib 5Whole-Body Irradiation 4Trimethoprim, Sulfamethoxazole Drug Combination 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2/3 × Leyk × Other hematologic neoplasm × Clear all
NCT00720109 2020-04-13

Dasatinib and Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

National Cancer Institute (NCI)

Phase 2/3 Completed
63 enrolled 13 charts
LymphoidOther hematologic neoplasm

Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡